<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230528058311N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-12</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of eight weeks of low-intensity endurance training with lower limb blood flow restriction on arterial blood pressure and cardiac function in patients with mild hypertension</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of eight-week low-intensity endurance training with lower limb blood flow restriction on arterial blood pressure, heart performance, and serum levels of PGC1-a, Klotho, and nitric oxide metabolites in patients with mild hypertension</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70412</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Basic scienece, Blinding description: Colleagues who participate in biochemical tests and data analysis do not  
  inform about the study groups. Samples sent to the laboratory
 will be numbered؛ additionally, for an individual who performs the data analysis, the study groups will be indistinctive.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Method of treaning to prevent high blood pressure and diminish the need to consume antihypertensive drugs..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: a group that rides a stationary bicycle at 50% VO2paek for 3 sessions a week, every other day, and each session is a maximum of 45 minutes for 8 weeks. Intervention 2: Intervention group: a group that rides a stationary bicycle 3 times a week, every other day, and each session is 45 minutes maximum for 8 weeks, with 50% of VO2paek, while the upper part of the thigh is closed with a cuff, blood flow restriction through closing The cuff will be applied in the proximal part of the thighs. The complete femoral artery occlusion pressure will be estimated through the following formula. Lower body arterial occlusion (mmHg) = (5.893 × thigh circumference) + (0.912 × systolic blood pressure) + (0.734 × diastolic blood pressure) 220.046 The cuff pressure in the exercises in the first and second weeks will be calculated and applied as 50% of the complete occlusion pressure (AOP). Intervention 3: Control group: Control group without exercise and  blood flow restriction.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The result of the study will be shared with the participants in the Rubika social network. and it will be published with Print the article.

When:
The beginning of the access period for participants in Rubika, immediately after obtaining the results and for the public after the publication of the article from 2025

To whom:
It will be available only to researchers working in academic and scientific institutions.

Conditions:
With the permission and discretion of the person in charge of the study, the data will be available to researchers working in academic and scientific institutions.

Where to obtain:
Afzalipur Faculty of Medicine, Department of Physiology by Dr. Siavash Jokar
Postal code: 7616914115
Email: Sjokar@gmail.com
09132985770

How to obtain:
The study documentation can be accessed by Correspondence with the principal investigator

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Siavash Jokar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>At the end of 22 Bahman Blvd., Shahid Bahonar University, Afzalipur Faculty of Medicine</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616914115</zip>
        <telephone>+98 34 3132 0500</telephone>
        <email>Sjokar@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Siavash Jokar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>At the end of 22 Bahman Blvd., Shahid Bahonar University, Afzalipur Faculty of Medicine</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616914115</zip>
        <telephone>+98 34 3132 0500</telephone>
        <email>Sjokar@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>50 - 64 years old
Body mass index (BMI) less than 30
Not consumption of blood pressure drugs
systolic blood pressure: 130-150mmHg ; diastolic blood pressure&gt;80 mmHg</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Secondary hypertension
Smoking
Heart, respiratory, kidney, liver, metabolic, and other chronic diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: a group that rides a stationary bicycle at 50% VO2paek for 3 sessions a week, every other day, and each session is a maximum of 45 minutes for 8 weeks.</i_keyword>
      <i_keyword>Intervention group: a group that rides a stationary bicycle 3 times a week, every other day, and each session is 45 minutes maximum for 8 weeks, with 50% of VO2paek, while the upper part of the thigh is closed with a cuff, blood flow restriction through closing The cuff will be applied in the proximal part of the thighs. The complete femoral artery occlusion pressure will be estimated through the following formula. Lower body arterial occlusion (mmHg) = (5.893 × thigh circumference) + (0.912 × systolic blood pressure) + (0.734 × diastolic blood pressure) 220.046 The cuff pressure in the exercises in the first and second weeks will be calculated and applied as 50% of the complete occlusion pressure (AOP).</i_keyword>
      <i_keyword>Control group: Control group without exercise and  blood flow restriction</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum PGC1α level. Timepoint: Before starting training and 24 hours after the last training session. Method of measurement: Elisa.</prim_outcome>
      <prim_outcome>Serum levels of Klotho. Timepoint: Before starting training and 24 hours after the last training session. Method of measurement: Elisa.</prim_outcome>
      <prim_outcome>Serum nitrite levels. Timepoint: Before starting training and 24 hours after the last training session. Method of measurement: Photometry.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Changes in blood pressure. Timepoint: One week after the intervention. Method of measurement: with a mercury barometer.</sec_outcome>
      <sec_outcome>Left ventricular ejection fraction. Timepoint: One week after the intervention. Method of measurement: Echocardiography by a cardiologist.</sec_outcome>
      <sec_outcome>Changes in biochemical parameters. Timepoint: One week after the intervention. Method of measurement: Elisa.</sec_outcome>
      <sec_outcome>Left ventricular fractional shortening. Timepoint: One week after the intervention. Method of measurement: Echocardiography.</sec_outcome>
      <sec_outcome>Left ventricular mass. Timepoint: One week after the intervention. Method of measurement: Echocardiography.</sec_outcome>
      <sec_outcome>Posterior wall thickness. Timepoint: One week after the intervention. Method of measurement: Echocardiography.</sec_outcome>
      <sec_outcome>Relative wall thickness. Timepoint: One week after the intervention. Method of measurement: Echocardiography.</sec_outcome>
      <sec_outcome>Isovolumic relaxation time. Timepoint: One week after the intervention. Method of measurement: Echocardiography.</sec_outcome>
      <sec_outcome>Mean left atrial pressure. Timepoint: One week after the intervention. Method of measurement: Echocardiography.</sec_outcome>
      <sec_outcome>Left ventricular end-systolic diameter. Timepoint: One week after the intervention. Method of measurement: Echocardiography.</sec_outcome>
      <sec_outcome>Left ventricular end-diastolic diameter. Timepoint: One week after the intervention. Method of measurement: Echocardiography.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Kerman University of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-30</approval_date>
        <contact_name>Ethics Committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>The beginning of Haft Bagh Alavi axis, University of Medical Sciences campus kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
